Progyny, Inc. (PGNY)
| Market Cap | 2.84B |
| Revenue (ttm) | 550.71M |
| Net Income (ttm) | 55.57M |
| Shares Out | 91.94M |
| EPS (ttm) | 0.56 |
| PE Ratio | 55.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,672,491 |
| Open | 30.21 |
| Previous Close | 29.70 |
| Day's Range | 29.36 - 31.00 |
| 52-Week Range | 25.67 - 68.32 |
| Beta | 2.03 |
| Analysts | Buy |
| Price Target | 60.18 (+94.5%) |
| Earnings Date | Aug 4, 2022 |
About PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimburseme... [Read more...]
Financial Performance
In 2021, Progyny's revenue was $500.62 million, an increase of 45.17% compared to the previous year's $344.86 million. Earnings were $65.77 million, an increase of 41.56%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for PGNY stock is "Buy." The 12-month stock price forecast is 60.18, which is an increase of 94.51% from the latest price.
News
AMN or PGNY: Which Is the Better Value Stock Right Now?
AMN vs. PGNY: Which Stock Is the Better Value Option?
PGNY STOCKHOLDER ALERT: Robbins LLP Reminds Investors it is Investigating Progyny, Inc. (PGNY) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $PGNY #InvestorsRights--Robbins LLP Reminds Investors it is Investigating Progyny, Inc. (PGNY) on Behalf of Shareholders
Progyny, Inc. to Present at the Jefferies 2022 Healthcare Conference
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, tod...
AMN vs. PGNY: Which Stock Is the Better Value Option?
AMN vs. PGNY: Which Stock Is the Better Value Option?
Progyny Lands Employer Benefits Expert in Expansion of Leadership Team
Arielle Bogorad joins Progyny as Senior Vice President of Employer Market Strategy Arielle Bogorad joins Progyny as Senior Vice President of Employer Market Strategy
PGNY STOCK NEWS: Robbins LLP Investigates Progyny, Inc. (PGNY) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $PGNY #classactionlawyers--PGNY STOCK NEWS: Robbins LLP Investigates Progyny, Inc. (PGNY) on Behalf of Shareholders
The Broken Brown Egg and Progyny Launch the Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couple...
The inaugural grant will provide education, access to care, and financial assistance to either a couple or individual of color through their family building journey The inaugural grant will provide educ...
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
Progyny (PGNY) delivered earnings and revenue surprises of 150% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Progyny: A Profitable High-Growth Company
Incorporated in 2008, Progyny Inc. ( PGNY , Financial) is a leading benefits management company operating in the fertility space in the United States. The company operates as a third-party insurance com...
Progyny, Inc. to Present at the BofA Securities 2022 Healthcare Conference
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, to...
Analysts Estimate Progyny (PGNY) to Report a Decline in Earnings: What to Look Out for
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny, Inc. Announces Details for Its First Quarter 2022 Results Report
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, wi...
Progyny and RESOLVE to Launch National Infertility Awareness Week® by Ringing the Nasdaq Stock Market Opening Bell an...
The fertility benefits leader and national infertility nonprofit association take over the capital of the world to support the millions of people who need family building support The fertility benefits ...
AVTR vs. PGNY: Which Stock Is the Better Value Option?
AVTR vs. PGNY: Which Stock Is the Better Value Option?
Moore Kuehn, PLLC Encourages Investors of Progyny, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ:...
Investors see growth opportunity in Femtech
Funding for so-called Femtech has more than tripled since 2015. Early stage investors see growth opportunities in companies like breast cancer imaging start-up Clairity, which are looking to close the g...
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?
OCDX vs. PGNY: Which Stock Is the Better Value Option?
Progyny, Inc. to Present at the Barclays Global Healthcare Conference
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, to...
Progyny (PGNY) Surpasses Q4 Earnings Estimates
Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny, Inc. Announces Fourth Quarter and Full Year 2021 Results
Issues Guidance for 2022, Reflecting 50% Revenue Growth at Midpoint of the RangeReports Full Year Revenue of $500.6 Million, Reflecting 45% GrowthReports Fourth Quarter Revenue of $127.6 Million, Reflec...
Earnings Preview: Progyny (PGNY) Q4 Earnings Expected to Decline
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2021 Results Report
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, wil...
Progyny, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, tod...
Is Progyny a good buy opportunity at the current share price?
Progyny, Inc (NASDAQ: PGNY) shares have weakened more than 20% since November 05, even though the company reported strong third-quarter results. Management expects a further business acceleration Progyn...
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).